Medicus Pharma Ltd. Common Stock (MDCX) is a publicly traded Healthcare sector company. As of May 21, 2026, MDCX trades at $0.29 with a market cap of $16.06M and a P/E ratio of -0.11. MDCX moved +5.00% today. Year to date, MDCX is -81.88%; over the trailing twelve months it is -96.19%. Its 52-week range spans $0.25 to $8.94. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces MDCX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Medicus Pharma Posts $9M Q1 Loss, Advances Phase 2 SkinJect® and Teverelix® Programs: Medicus Pharma reported $6.4m in cash at March 31, 2026 (up from $4.0m a year earlier) while net loss widened to $9.0m. The company disclosed positive Phase 2 SKNJCT-003 data demonstrating dose-response in the 200-µg cohort for basal cell carcinoma and FDA clearance for a Phase 2b Teverelix® study.
| Metric | Value |
|---|---|
| Price | $0.29 |
| Market Cap | $16.06M |
| P/E Ratio | -0.11 |
| EPS | $-2.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.94 |
| 52-Week Low | $0.25 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $-221.25K |
| Net Income | $-39.38M |
| Gross Margin | 0.00% |
2 analysts cover MDCX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.